COLL Q1 2020 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q1 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$77M+2.7% YoY

Gross Profit

$39M51.0% margin

Operating Income

$5M6.6% margin

Net Income

$450,0000.6% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+3.1%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$8M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$635M

Total Liabilities

$494M

Stockholders' Equity

$141M

Cash & Equivalents

$116M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$77M	$75M	+2.7%
Gross Profit	$39M	$25M	+53.8%
Operating Income	$5M	-$10M	+150.7%
Net Income	$450,000	-$10M	+104.6%

Revenue Segments

Nucynta

$45M37%

Xtampza

$32M26%

Nucynta Ir

$28M23%

Nucynta Er

$17M14%